Nothing Special   »   [go: up one dir, main page]

MX2023002308A - Polimorfos de un inhibidor de ssao. - Google Patents

Polimorfos de un inhibidor de ssao.

Info

Publication number
MX2023002308A
MX2023002308A MX2023002308A MX2023002308A MX2023002308A MX 2023002308 A MX2023002308 A MX 2023002308A MX 2023002308 A MX2023002308 A MX 2023002308A MX 2023002308 A MX2023002308 A MX 2023002308A MX 2023002308 A MX2023002308 A MX 2023002308A
Authority
MX
Mexico
Prior art keywords
polymorphs
ssao inhibitor
methods
ssao
inhibitor
Prior art date
Application number
MX2023002308A
Other languages
English (en)
Inventor
David Michael Remick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2023002308A publication Critical patent/MX2023002308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

En la presente descripción se proporcionan polimorfos de (2E)-3-fluoro-2-({[2-(4-metoxipiperidin-1-il)pirimidin-5-il]oxi}m etil)prop-2-en-1-aminio 4-metilbencenosulfonato, composiciones de los mismos, métodos de preparación de los mismos y métodos de uso de los mismos.
MX2023002308A 2020-08-25 2021-08-24 Polimorfos de un inhibidor de ssao. MX2023002308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070147P 2020-08-25 2020-08-25
PCT/US2021/047363 WO2022046779A1 (en) 2020-08-25 2021-08-24 Polymorphs of an ssao inhibitor

Publications (1)

Publication Number Publication Date
MX2023002308A true MX2023002308A (es) 2023-07-11

Family

ID=80355663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002308A MX2023002308A (es) 2020-08-25 2021-08-24 Polimorfos de un inhibidor de ssao.

Country Status (14)

Country Link
US (2) US11820754B2 (es)
EP (1) EP4204405A4 (es)
JP (1) JP2023539639A (es)
KR (1) KR20230058112A (es)
CN (1) CN116615416A (es)
AU (1) AU2021332217A1 (es)
CA (1) CA3193057A1 (es)
CL (1) CL2023000537A1 (es)
CO (1) CO2023002085A2 (es)
IL (1) IL300853A (es)
MX (1) MX2023002308A (es)
PE (1) PE20231096A1 (es)
TW (1) TW202227406A (es)
WO (1) WO2022046779A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4204405A4 (en) 2020-08-25 2024-05-29 Eli Lilly and Company POLYMORPHS OF AN SSAO INHIBITOR

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
WO2008123469A1 (ja) 2007-03-30 2008-10-16 Japan Tobacco Inc. ６員環アミド化合物およびその用途
DK2170403T3 (da) 2007-06-27 2014-06-16 Quark Pharmaceuticals Inc Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
JP2010533658A (ja) 2007-07-20 2010-10-28 メルク フロスト カナダ リミテツド ステアロイル補酵素ａデルタ−９デサチュラーゼ阻害剤としての二環性へテロ芳香族化合物
JP2011504485A (ja) 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
EP2390254A1 (en) 2009-01-22 2011-11-30 Mitsubishi Tanabe Pharma Corporation NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
US20110014558A1 (en) 2009-07-15 2011-01-20 Kabushiki Kaisha Toshiba Developing agent and method for producing the same
JP2011136942A (ja) 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
CA2830157C (en) 2011-03-15 2019-02-26 Astellas Pharma Inc. Guanidine compound
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
SG11201406948PA (en) 2012-05-02 2014-11-27 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CA2891569A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
US8962641B2 (en) 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
WO2014184104A1 (en) 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
PT3057586T (pt) 2013-10-18 2020-03-13 Celgene Quanticel Res Inc Inibidores de bromodomínio
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
EP3437659B1 (en) 2016-03-28 2023-03-01 Intercept Pharmaceuticals, Inc. Combination of a fxr agonist and an angiotensin ii receptor blocker
IL311687A (en) 2016-03-31 2024-05-01 Genfit Methods for treating gallstone disease
EP3463373A4 (en) 2016-05-25 2020-04-22 Akarna Therapeutics, Ltd. COMBINATIONS USING FARNESOID X RECEPTOR (FXR) MODULATORS
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
KR20190070956A (ko) 2016-10-19 2019-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
CN108883185B (zh) 2016-12-06 2021-10-08 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
CN108341752B (zh) 2017-01-21 2022-12-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
ES2959842T3 (es) 2017-02-21 2024-02-28 Genfit Combinación de un agonista de PPAR con un agonista de FXR
EP3595656A1 (en) 2017-03-13 2020-01-22 Genfit Pharmaceutical compositions for combination therapy
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
CN109251166B (zh) 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
AU2018320715A1 (en) 2017-08-25 2020-02-13 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
WO2019053233A1 (en) 2017-09-18 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
WO2019094777A1 (en) 2017-11-13 2019-05-16 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
WO2019209738A1 (en) 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
WO2019241751A1 (en) 2018-06-15 2019-12-19 Metacrine, Inc. Ssao inhibitors and uses thereof
CN112771026A (zh) 2018-08-30 2021-05-07 拓臻制药公司 治疗肝脏病症
US20220047553A1 (en) 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
JP2022504697A (ja) 2018-10-24 2022-01-13 メタクリン，インク． Ｓｓａｏ阻害剤とその使用
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
KR20220041104A (ko) 2019-07-23 2022-03-31 노파르티스 아게 Fxr 작용제를 포함하는 치료
EP4003349A1 (en) 2019-07-23 2022-06-01 Novartis AG Combination treatment of liver diseases using fxr agonists
CN115666577A (zh) 2020-03-25 2023-01-31 拓臻股份有限公司 呼吸道病症的治疗
KR20230023642A (ko) 2020-05-13 2023-02-17 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
CA3183413A1 (en) 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
EP4204405A4 (en) 2020-08-25 2024-05-29 Eli Lilly and Company POLYMORPHS OF AN SSAO INHIBITOR
AU2022384271A1 (en) 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor
CA3238082A1 (en) 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders

Also Published As

Publication number Publication date
CL2023000537A1 (es) 2023-12-15
AU2021332217A1 (en) 2023-05-11
EP4204405A1 (en) 2023-07-05
US11820754B2 (en) 2023-11-21
JP2023539639A (ja) 2023-09-15
TW202227406A (zh) 2022-07-16
US20220089563A1 (en) 2022-03-24
CA3193057A1 (en) 2022-03-03
CO2023002085A2 (es) 2023-03-07
US20240308975A1 (en) 2024-09-19
WO2022046779A1 (en) 2022-03-03
IL300853A (en) 2023-04-01
PE20231096A1 (es) 2023-07-18
KR20230058112A (ko) 2023-05-02
CN116615416A (zh) 2023-08-18
EP4204405A4 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
WO2022155530A8 (en) Variant strain-based coronavirus vaccines
AR075501A1 (es) Uso de inhibidores de la succinato deshidrogenasa para combatir infecciones primarias por oidio
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CA2589726C (en) Graphical user interface for tissue biopsy system
PE20141408A1 (es) Aminoquinazolinas como inhibidores de quinasa
MD3319967T2 (ro) Compuşi inhibitori ai căii de semnalizare Notch
PH12019501639A1 (en) Jaki selective inhibitors
MX2023002308A (es) Polimorfos de un inhibidor de ssao.
UY38377A (es) Piridazinonas y sus métodos de uso
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
BR112022003357A2 (pt) Compostos heterocíclicos
PH12021550048A1 (en) Selective estrogen receptor degraders.
MX2022015597A (es) Formas en estado solido de ciantraniliprol.
EA202191833A1 (ru) Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
EP4438127A3 (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
MX2021008295A (es) Formas sólidas que comprenden (s)-4-(4-(4-(((2-(2,6-dioxopiperidin -3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fl uorobenzonitrilo y sales del mismo, composiciones que comprenden y métodos de utilización del mismo.
EA200501247A1 (ru) Ингибитор белка резистентности рака молочной железы (bcrp)
ZA202310682B (en) Nicotinamide ripk1 inhibitors
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
BR112022007107A2 (pt) Método para a síntese de um composto
PH12022550497A1 (en) Perk inhibiting compounds
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
AU2020235128A8 (en) Transparent or semitransparent inverse microlatices of polyacrylamide as oil emulsion drift reducing agent